Literature DB >> 26967715

Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward.

Kevin Jon Williams1, Xiangdong Wu2.   

Abstract

The growing worldwide prevalence of overnutrition and underexertion threatens the gains that we have made against atherosclerotic cardiovascular disease and other maladies. Chronic overnutrition causes the atherometabolic syndrome, which is a cluster of seemingly unrelated health problems characterized by increased abdominal girth and body-mass index, high fasting and postprandial concentrations of cholesterol- and triglyceride-rich apoB-lipoproteins (C-TRLs), low plasma HDL levels, impaired regulation of plasma glucose concentrations, hypertension, and a significant risk of developing overt type 2 diabetes mellitus (T2DM). In addition, individuals with this syndrome exhibit fatty liver, hypercoagulability, sympathetic overactivity, a gradually rising set-point for body adiposity, a substantially increased risk of atherosclerotic cardiovascular morbidity and mortality, and--crucially--hyperinsulinemia. Many lines of evidence indicate that each component of the atherometabolic syndrome arises, or is worsened by, pathway-selective insulin resistance and responsiveness (SEIRR). Individuals with SEIRR require compensatory hyperinsulinemia to control plasma glucose levels. The result is overdrive of those pathways that remain insulin-responsive, particularly ERK activation and hepatic de-novo lipogenesis (DNL), while carbohydrate regulation deteriorates. The effects are easily summarized: if hyperinsulinemia does something bad in a tissue or organ, that effect remains responsive in the atherometabolic syndrome and T2DM; and if hyperinsulinemia might do something good, that effect becomes resistant. It is a deadly imbalance in insulin action. From the standpoint of human health, it is the worst possible combination of effects. In this review, we discuss the origins of the atherometabolic syndrome in our historically unprecedented environment that only recently has become full of poorly satiating calories and incessant enticements to sit. Data are examined that indicate the magnitude of daily caloric imbalance that causes obesity. We also cover key aspects of healthy, balanced insulin action in liver, endothelium, brain, and elsewhere. Recent insights into the molecular basis and pathophysiologic harm from SEIRR in these organs are discussed. Importantly, a newly discovered oxide transport chain functions as the master regulator of the balance amongst different limbs of the insulin signaling cascade. This oxide transport chain--abbreviated 'NSAPP' after its five major proteins--fails to function properly during chronic overnutrition, resulting in this harmful pattern of SEIRR. We also review the origins of widespread, chronic overnutrition. Despite its apparent complexity, one factor stands out. A sophisticated junk food industry, aided by subsidies from willing governments, has devoted years of careful effort to promote overeating through the creation of a new class of food and drink that is low- or no-cost to the consumer, convenient, savory, calorically dense, yet weakly satiating. It is past time for the rest of us to overcome these foes of good health and solve this man-made epidemic.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chronic overnutrition; Clinical harm; Imbalanced insulin action; Molecular mechanisms; Signaling

Mesh:

Substances:

Year:  2016        PMID: 26967715     DOI: 10.1016/j.atherosclerosis.2016.02.004

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  24 in total

1.  Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1.

Authors:  Keyang Chen; Qingsi Wu; Kongwang Hu; Chengwei Yang; Xiangdong Wu; Peter Cheung; Kevin Jon Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-21       Impact factor: 8.311

Review 2.  The impact of glucose-lowering medications on cardiovascular disease.

Authors:  Angelo Avogaro; Saula Vigili De Kreutzenberg; Gian Paolo Fadini
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-02-14

3.  Myeloid-specific deletion of Zfp36 protects against insulin resistance and fatty liver in diet-induced obese mice.

Authors:  Valentina Caracciolo; Jeanette Young; Donna Gonzales; Yingchun Ni; Stephen J Flowers; Ross Summer; Scott A Waldman; Jason K Kim; Dae Young Jung; Hye Lim Noh; Taekyoon Kim; Perry J Blackshear; Danielle O'Connell; Robert C Bauer; Caleb B Kallen
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

Review 4.  Insulin resistance in obesity: an overview of fundamental alterations.

Authors:  Rocco Barazzoni; Gianluca Gortan Cappellari; Maurizio Ragni; Enzo Nisoli
Journal:  Eat Weight Disord       Date:  2018-02-03       Impact factor: 4.652

5.  Use of BMI as the marker of adiposity in a metabolic syndrome severity score: Derivation and validation in predicting long-term disease outcomes.

Authors:  Matthew J Gurka; Stephanie L Filipp; Solomon K Musani; Mario Sims; Mark D DeBoer
Journal:  Metabolism       Date:  2018-02-02       Impact factor: 8.694

6.  Ethnic Variation in the Association of Hypertension With Type 2 Diabetes.

Authors:  Moran Blaychfeld-Magnazi; Hilla Knobler; Hillary Voet; Naama Reshef; Shimon Weitzman; Anne E Sumner; Taiba Zornitzki
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-02       Impact factor: 3.738

7.  Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-h insulin partially mediating this unidirectional relationship: a prospective cohort study.

Authors:  Tianshu Han; Yu Cheng; Shuang Tian; Li Wang; Xi Liang; Wei Duan; Lixin Na; Changhao Sun
Journal:  Cardiovasc Diabetol       Date:  2016-11-04       Impact factor: 9.951

Review 8.  Hyperinsulinemia: a Cause of Obesity?

Authors:  Karel A Erion; Barbara E Corkey
Journal:  Curr Obes Rep       Date:  2017-06

9.  Insulin and diet-induced changes in the ubiquitin-modified proteome of rat liver.

Authors:  Shilpa R Nagarajan; Amanda E Brandon; Jessie A McKenna; Harrison C Shtein; Thinh Q Nguyen; Eurwin Suryana; Philip Poronnik; Gregory J Cooney; Darren N Saunders; Andrew J Hoy
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

10.  Insulin therapy for type 2 diabetes - are we there yet? The d-Nav® story.

Authors:  I Hodish
Journal:  Clin Diabetes Endocrinol       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.